Advertisement
Advertisement

CORT

CORT logo

Corcept Therapeutics Inc

51.47
USD
+0.32
+0.63%
Dec 20, 15:59 UTC -5
Closed
...

Corcept Therapeutics Inc Profile

About

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery.

Info & Links

CEO

Joseph K. Belanoff

Headquarters

149 COMMONWEALTH DRIVE
MENLO PARK, CA 94025, UNITED STATES

Industry

Pharmaceuticals Major

Sector

Health Technology

Website

www.corcept.com

Auditor

Ernst & Young LLP

Share holders

379

Employees

352

Corcept Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

5.39B

Enterprise Value

5.26B

Enterprise Value/EBITDA(ttm)

38.87

Price to Earnings Ratio(ttm)

40.60

Price to Sales(ttm)

8.53

Price to Book(mrq)

8.39

Price to Cash(ytd)

53.40

Profitability

Gross Margin(ttm)

98.44%

Operating Margin(ttm)

22.35%

Profit Margin(ttm)

22.19%

Return on Equity(ttm)

24.54%

Return on Invested Capital(ttm)

24.52%

Return on Assets(ttm)

20.24%

Income Statement

Revenue(ttm)

628.55M

Revenue Per Share(ttm)

6.00

Gross Profit(ttm)

618.75M

EBITDA(ttm)3

135.38M

Net Income Available to Common(ttm)

140.49M

Diluted EPS(ttm)

1.26

Share Statistics

Beta (5Y Monthly)

0.51

52-Week Change

96.00%

S&P 500 52-Week Change

24.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

104.78M

Dividend Yield

0.00%

Float4

83.30M

% Held by Insiders

20.50%

% Held by Institutions

93.61%

Balance Sheet

Total Cash(mrq)

380.34M

Total Cash Per Share(mrq)

3.63

Total Debt(mrq)

6.36M

Total Debt/Equity(mrq)

1.00%

Current Ratio(mrq)

3.70%

Quick Ratio(mrq)

3.64%

Book Value Per Share(mrq)

6.10

Cash Flow

Operating Cash Flow Per Share(ytd)

1.22

Free Cash Flow(ytd)

136.72M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement